{"title":"Evaluation of a Novel <i>MAGEC1</i> Variant and Susceptibility to Ovarian Cancer in the North Indian Population.","authors":"Minerva Sharma, Sonali Verma, Vanshika Bhagat, Ziya Tufail, Rajeshwer Singh Jamwal, Bhawani Sharma, Gresh Chander, Ruchi Shah, Audesh Bhat, Manushi Dhar, Supinder Singh, Rakesh Kumar","doi":"10.1089/gtmb.2025.0029","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Objective:</i></b> To check the correlation between the MAGE Family Member C1 (<i>MAGEC1)</i> gene variant rs176036 and ovarian cancer risk among the Jammu and Kashmir population. <b><i>Methodology:</i></b> A case-control association study of the <i>MAGEC1</i> gene variant rs176036 (G > A) and ovarian cancer. The variation was identified through whole exome sequencing, and the selected variant was genotyped in 111 patients with ovarian cancer and 107 healthy controls belonging to the Jammu and Kashmir region of North India using Sanger sequencing to confirm its association with the ovarian cancer. Odds ratio (OR) and other statistical values were calculated using standard tools. <b><i>Results:</i></b> The allelic frequency distribution was found to be similar between cases and controls, with the dominant allele (G) present in 89.6% of cases and 90.2% of controls (<i>p</i> = 0.84). The allelic OR for the dominant allele was 1.08 (0.55-2.11), which is nonsignificant (<i>p</i> = 0.83). <b><i>Conclusion:</i></b> The present study suggests that the rs176036 variant does not confer any increased risk of ovarian cancer among population of Jammu and Kashmir.</p>","PeriodicalId":12603,"journal":{"name":"Genetic testing and molecular biomarkers","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetic testing and molecular biomarkers","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1089/gtmb.2025.0029","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To check the correlation between the MAGE Family Member C1 (MAGEC1) gene variant rs176036 and ovarian cancer risk among the Jammu and Kashmir population. Methodology: A case-control association study of the MAGEC1 gene variant rs176036 (G > A) and ovarian cancer. The variation was identified through whole exome sequencing, and the selected variant was genotyped in 111 patients with ovarian cancer and 107 healthy controls belonging to the Jammu and Kashmir region of North India using Sanger sequencing to confirm its association with the ovarian cancer. Odds ratio (OR) and other statistical values were calculated using standard tools. Results: The allelic frequency distribution was found to be similar between cases and controls, with the dominant allele (G) present in 89.6% of cases and 90.2% of controls (p = 0.84). The allelic OR for the dominant allele was 1.08 (0.55-2.11), which is nonsignificant (p = 0.83). Conclusion: The present study suggests that the rs176036 variant does not confer any increased risk of ovarian cancer among population of Jammu and Kashmir.
期刊介绍:
Genetic Testing and Molecular Biomarkers is the leading peer-reviewed journal covering all aspects of human genetic testing including molecular biomarkers. The Journal provides a forum for the development of new technology; the application of testing to decision making in an increasingly varied set of clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. This is the definitive resource for researchers, clinicians, and scientists who develop, perform, and interpret genetic tests and their results.
Genetic Testing and Molecular Biomarkers coverage includes:
-Diagnosis across the life span-
Risk assessment-
Carrier detection in individuals, couples, and populations-
Novel methods and new instrumentation for genetic testing-
Results of molecular, biochemical, and cytogenetic testing-
Genetic counseling